Products
Iscalimab Biosimilar Monoclonal Antibody (CD40) for Research
Pre-Made Iscalimab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
CFZ533 (ISCALIMAB) is a fully human antibody that blocks CD40, a co-stimulatory protein involved in the activation of immune B-cells, which are crucial to the development of Sjogren's syndrome. It is currently in Phase II of clinical trial for Sjogren's Syndrome.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-280-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Iscalimab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody |
| INN Name | Iscalimab |
| Target | CD40 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Novartis;XOMA |
| Conditions Approved | na |
| Conditions Active | Graves' disease;Lupus nephritis;Myasthenia gravis;Renal transplant rejection;Sjogren's syndrome;Systemic lupus erythematosus |
| Conditions Discontinued | Rheumatoid arthritis |
| Development Tech | na |
About target - CD40
1. Protein CD40 ligand
2. Gene CD40
3. Organism Homo sapiens (Human)
Function
Cytokine that acts as a ligand to CD40/TNFRSF5 (PubMed:1280226, PubMed:31331973).
Costimulates T-cell proliferation and cytokine production (PubMed:8617933).
Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation (PubMed:8617933).
Induces the activation of NF-kappa-B (PubMed:15067037, PubMed:31331973).
Induces the activation of kinases MAPK8 and PAK2 in T-cells (PubMed:15067037).
Induces tyrosine phosphorylation of isoform 3 of CD28 (PubMed:15067037).
Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4 (By similarity).
Involved in immunoglobulin class switching (By similarity).
CD40 ligand, soluble form:
Acts as a ligand for integrins, specifically ITGA5:ITGB1 and ITGAV:ITGB3; both integrins and the CD40 receptor are required for activation of CD40-CD40LG signaling, which have cell-type dependent effects, such as B-cell activation, NF-kappa-B signaling and anti-apoptotic signaling.
